Creating Personalized Medicines

For two decades, PMC has tracked the growing number of personalized medicines coming to the market. The Coalition’s latest research shows that personalized medicines, meaning those whose labels reference biomarker-based targeting strategies, accounted for at least 25 percent of new U.S. Food and Drug Administration-approved drugs for each of the last eight years, up from next to none 20 years ago.

But economic and political landscapes have begun to shift, raising questions about the extent to which future market dynamics will continue to incentivize the development of personalized medicines that two-thirds of Americans say they prefer over one-size-fits-all therapies.

In this context, four biopharmaceutical industry executives will discuss their views on the future of personalized medicine, including gene and cell-based therapies, in today’s drug development environment.

During this discussion, PhRMA Vice President for Policy and Research Randy Burkholder will engage the panelists in a wide-ranging conversation about the scientific, business, and public policy-based factors that could impact the industry’s plans to develop personalized medicines in the future.